Ocular Therapeutix gets subpoena from SEC over eye pain drug

Shutterstock photo

Dec 22 (Reuters) - Ocular Therapeutix Inc said on Friday the U.S. Securities and Exchange Commission (SEC) had issued a subpoena seeking information about the company's eye-pain drug Dextenza.

Shares of the company were down 7.2 percent at $4.25 in after-marketing trading.

The subpoena included a request to furnish Dextenza-related communications with the U.S. Food and Drug Administration (FDA), investors and others, the company said.

Ocular also said some of its current and former executives and board members were named in a lawsuit for alleged breach of fiduciary duty.

The company said it intends to cooperate with the SEC.

This article appears in: Stocks
Referenced Symbols: OCUL

More from Reuters


See headlines for OCUL

Research Brokers before you trade

Want to trade FX?